Health economic impact of liquid biopsies in cancer management

References

• Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013 Nov;14(12):1165–1174.
   PubMed Web of Science ®Google Scholar
• Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015 Mar;24(3):294–301.
   PubMed Web of Science ®Google Scholar
• Van Harten W, IJzerman MJ. Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments. Ecancermedicalscience. 2017;11:ed71.
   PubMedGoogle Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016 Aug 20;34(24):2925–2934.
   PubMed Web of Science ®Google Scholar
• Del Paggio JC, Azariah B, Sullivan R, et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann Oncol. 2017 Jan 1;28(1):157–162.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ann Sakowski J, Trosman J, et al. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Jan 1;16(3):251–257. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018 Jan 18;1:eaar3247–10.
   Google Scholar
• Bardelli A, Pantel K. Liquid Biopsies, what we do not know (yet). Cancer Cell. 2017 Feb 13;31(2):172–179.
   PubMed Web of Science ®Google Scholar
• Onstenk W, Gratama JW, Foekens JA, et al. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev. 2013 Nov;39(7):691–700.
   PubMed Web of Science ®Google Scholar
• Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Australasian Med J. 1869;14:146–149.
   Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res Am Assoc Cancer Res. 2004 Oct 15;10(20):6897–6904.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781–791. Massachusetts Medical Society.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJA, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Jul 1;26(19):3213–3221.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res Am Assoc Cancer Res. 2008 Oct 1;14(19):6302–6309.
   PubMed Web of Science ®Google Scholar
• Lv Q, Gong L, Zhang T, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin Transl Oncol. 2016 Mar;18(3):322–330. Springer Milan.
   PubMed Web of Science ®Google Scholar
• Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase iii trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Mar 10;32(11):1136–1142.
   PubMed Web of Science ®Google Scholar
• Hardingham JE, Grover P, Winter M, et al. Detection and clinical significance of circulating tumor cells in colorectal Cancer–20 years of progress. Mol Med. 2015 Oct 27;21(Suppl1):S25–31.
   PubMedGoogle Scholar
• Syrigos K, Fiste O, Charpidou A, et al. Circulating tumor cells count as a predictor of survival in lung cancer. Crit Rev Oncol Hematol. 2018 Mar 7;125:60–68.
   PubMed Web of Science ®Google Scholar
• Janni WJ, Rack B, Terstappen LWMM, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res. 2016 May 15;22(10):2583–2593.
   PubMed Web of Science ®Google Scholar
• Van Dalum G, Stam G-J, Scholten LFA, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015 Mar;46(3):1361–1368. Spandidos Publications.
   PubMed Web of Science ®Google Scholar
• Lianidou ES. Gene expression profiling and DNA methylation analyses of CTCs. Mol Oncol. 2016 Mar 1;10(3):431–442. Pantel K, Alix-Panabières C, editors.
   PubMed Web of Science ®Google Scholar
• Bernabé R, Hickson N, Wallace A, et al. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? Eur J Cancer. 2017 Jun;10(81):66–73.
   Google Scholar
• O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017 Mar;14(3):169–186.
   PubMed Web of Science ®Google Scholar
• Thariani R, Veenstra DL, Carlson JJ, et al. Paying for personalized care: cancer biomarkers and comparative effectiveness. Mol Oncol. 2012 Apr;6(2):260–266.
   PubMed Web of Science ®Google Scholar
• Khoury MJ, Berg A, Coates R, et al. The evidence dilemma in genomic medicine. Health Aff. 2008 Nov 1;27(6):1600–1611.
   Web of Science ®Google Scholar
• Lee DW, Neumann PJ, Rizzo JA. Understanding the medical and nonmedical value of diagnostic testing. Value Health. 2010 Mar;13(2):310–314.
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LWMM. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
   PubMedGoogle Scholar
• Krebs MG, Renehan AG, Backen A, et al. Circulating tumor cell enumeration in a phase ii trial of a four-drug regimen in advanced colorectal cancer. Clin Colorectal Cancer. 2015 Jun;14(2):115–22.e1–2.
   PubMed Web of Science ®Google Scholar
• Coumans FAW, Ligthart ST, Uhr JW, et al. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 2012 Oct 15;18(20):5711–5718. American Association for Cancer Research.
   PubMed Web of Science ®Google Scholar
• Coumans FAW, Ligthart ST, Terstappen LWMM. Interpretation of changes in circulating tumor cell counts. Transl Oncol. 2012 Dec 1;5(6):486–IN4.
   PubMed Web of Science ®Google Scholar
• Lorente D, Olmos D, Mateo J, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol. 2016 Dec;70(6):985–992.
   PubMed Web of Science ®Google Scholar
• Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase iii clinical trials. J Clin Oncol. 2017 Dec 22;36(6):572–580. American Society of Clinical Oncology.
   PubMedGoogle Scholar
• Degeling K, Schivo S, Mehra N, et al. Comparison of timed automata with discrete event simulation for modeling of biomarker-based treatment decisions: an illustration for metastatic castration-resistant prostate cancer. Value in Health. 2017 Jul; in press(10):1411–1419.
   Google Scholar
• Markowski MC, Frick KD, Eshleman JR, et al. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate. 2016 Dec;76(16):1484–1490.
   PubMed Web of Science ®Google Scholar
• Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. JNCI J Natl Cancer Inst. 2014 May 15;106(5):793.
   Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218–4224.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005 Dec 1;23(7):1420–1430.
   PubMed Web of Science ®Google Scholar
• Bidard F-C, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014 Apr;15(4):406–414.
   PubMed Web of Science ®Google Scholar
• Berghuis AMS, Koffijberg H, Prakash J, et al. Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility. Int J Mol Sci. 2017 Feb 9;18(2).
   PubMed Web of Science ®Google Scholar
• Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006 Nov 1;12(21):6403–6409.
   PubMed Web of Science ®Google Scholar
• Bidard F-C, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013 Jun;32(1–2):179–188.
   PubMed Web of Science ®Google Scholar
• Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014 Oct 13;32(31):3483–3490.
   PubMed Web of Science ®Google Scholar
• Bidard F-C, Pierga J-Y. Clinical utility of circulating tumor cells in metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1622–2.
   PubMed Web of Science ®Google Scholar
• Schramm A, Friedl TWP, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2016 9;Sep(293):271–281.
   Google Scholar
• De Gregorio A, Friedl TWP, Huober J, et al. Discordance in human epidermal growth factor receptor 2 (her2) phenotype between primary tumor and circulating tumor cells in women with HER2-negative metastatic breast cancer. JCO Precision Oncology. 2017 Sep;(1):1–12.
   Google Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 Feb;15(2):81–94. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Corcoran RB. Monitoring resistance through liquid biopsy. Ann Oncol. 2018 Jan 1;29(1):8–11.
   PubMed Web of Science ®Google Scholar
• Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med. 2006 Jul;8(7):448–450.
   PubMed Web of Science ®Google Scholar
• Burke W. Clinical validity and clinical utility of genetic tests. curr protoc hum genet. Hoboken NJ, eds. USA: John Wiley & Sons, Inc; 2009 Jan. Chapter 9: Unit9. 15–9.15.7.
   Google Scholar
• Ibáñez De Cáceres I, Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin Transl Oncol. 2007 Jul 9;(7):429–437.
   PubMed Web of Science ®Google Scholar
• Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017 Jun;22(3):421–430.
   PubMed Web of Science ®Google Scholar
• Miquel-Cases A, Schouten PC, Steuten LMG, et al. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treat Rev. 2017 Jan;52:117–127.
   PubMed Web of Science ®Google Scholar
• IJzerman MJ, Koffijberg H, Fenwick E, et al. Emerging use of early health technology assessment in medical product development: a scoping review of the literature. Pharmacoeconomics. 2017 Apr 21;35(7):727–740.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Liang S-Y, Van Bebber S. Canpers research group. challenges to the translation of genomic information into clinical practice and health policy: utilization, preferences and economic value. Curr Opin Mol Ther. 2008 Jun;10(3):260–266.
   PubMedGoogle Scholar
• Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health. 2013 Sep;16(6 Suppl):S32–8.
   PubMed Web of Science ®Google Scholar
• Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2010 Feb;94(2):91–100.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Veenstra D, Tunis SR, et al. How comparative effectiveness research can help advance “personalized medicine” in cancer treatment. Health Aff. 2011 Dec 5;30(12):2259–2268.
   Web of Science ®Google Scholar
• Towse A, Garrison LP. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health. 2013 Sep;16(6 Suppl):S39–43.
   PubMed Web of Science ®Google Scholar
• Schneider D, Bianchini G, Horgan D, et al. Establishing the evidence bar for molecular diagnostics in personalised cancer care. Public Health Genomics. 2015;18(6):349–358.
   PubMed Web of Science ®Google Scholar
• Wauters E, Vansteenkiste J. Will liquid biopsies become our fluid transition to personalized immunotherapy? Ann Oncol. 2018 Jan 1;29(1):11–13.
   PubMed Web of Science ®Google Scholar
• Bardia A, Haber DA. Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014 Nov 1;32(31):3470–3471.
   PubMed Web of Science ®Google Scholar
• Tarazona N, Cervantes A. Liquid biopsy: another tool towards tailored therapy in colorectal cancer. Ann Oncol. 2018 Jan 1;29(1):7–8.
   PubMed Web of Science ®Google Scholar
• Williams PM, Conley BA. Clinical application of liquid biopsies. JAMA Oncol. 2016 Aug 1;2(8):1003–1005. American Medical Association.
   PubMed Web of Science ®Google Scholar
• Friedrich MJ. Going with the flow: the promise and challenge of liquid biopsies. JAMA: Journal Am Med Assoc. 2017 Sep;26:1095–1097. American Medical Association.
   Google Scholar
• Rogowski WH, John J, IJzerman MJ. Translational health economics. in: world scientific handbook of global health economics and public policy. 3rd ed ed. Singapore: Munich, Germany: World Scientific Publishing Company; 2016.
   Google Scholar
• Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013 Sep;16(6 Suppl):S20–6.
   PubMed Web of Science ®Google Scholar
• Degeling K, Koffijberg H, IJzerman MJ. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):17–25. Taylor & Francis.
   PubMed Web of Science ®Google Scholar